The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Using vaccines to impart a long-term response in lenalidomide-treated MM
Ivan Marques Borrello, MD, from the John Hopkins School of Medicine, Baltimore, MD, USA, describes the potential of applying vaccines following chemotherapy to impart a long-term therapeutic response in patients with multiple myeloma (MM). One such vaccine, GVAX, will soon undergo a randomised trial in combination with lenalidomide, compared to lenalidomide alone, on patients with MM who are undergoing a lenalidomide regimen. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
